Home » Newsletters » BioWorld Science

BioWorld Science

April 11, 2013

View Archived Issues

Aftins, a chemical model of Alzheimer's disease in mice

NVP-LGB321, a novel orally bioavailable pan-pim kinase inhibitor

Discovery of a novel IDO pathway inhibitor for cancer-associated immunosuppression

Use of gene therapy as a treatment for congenital blindness

Preclinical development of an anticancer antibody with a unique mechanism of action

New DYRK inhibitors disclosed at AACR meeting

Amgen presents novel potent and orally bioavailable dual kinase inhibitor

Cell>Point reports results from phase IIa cardiovascular study

Development of a new dual EGFR/IGF1R inhibitor

PeptiDream and Ipsen partner on the development of therapeutic peptides

Encouraging findings from phase IIb study of tarafenacin in overactive bladder

H7N9 Replikins vaccine ready for testing

Amorfix Life Sciences reveals latest tumor study findings

Daiichi Sankyo discloses new DGAT1 inhibitors

Novel trypsin inhibitors for renal disorders patented by Astellas Pharma

Scientists at Daiichi Sankyo patent new TAFI inhibitors

Suzhou NeuPharma synthesizes new B-raf and KDR inhibitors

Bayer HealthCare to expand alliance with German Cancer Research Center

Dosing begins in phase II trial of ATL-1103 for the treatment of acromegaly

Pieris and Sanofi expand ongoing discovery and development partnership

FDA grants breakthrough therapy designation to Pfizer's palbociclib

FDA accepts Merck & Co.'s NDA for tablet formulation of antifungal agent

Kowa completes phase III K-115 study

NEI opens study of gevokizumab for noninfectious anterior scleritis

Phase I study of PLX-PAD in PAH cleared to begin

Phase II trial approved for BL-8040

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.